National Cancer Institute
31 Center Drive, Building 31, Bethesda, MD, 20814, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Levee Medical | Sep 2026Led | $2 MGrant | |
Tempo Therapeutics | Sep 2026Led | $1 MGrant | |
Illuminant Surgical | Apr 2026Participated | $8 MSeed | |
Vivere Oncotherapies | Jan 2026Participated | $10 MOther Equity | |
mPath Health | Mar 2024Participated | $1 MOther Equity | |
Modifi Bio | Oct 2022Led | $2 MGrant | |
miRecule | May 2021Participated | $6 MSeed | |
Outcomes4Me | Nov 2020Participated | $5 MOther Equity | |
Agilvax | Aug 2020Led | $1 MGrant | |
Tvardi Therapeutics | Jul 2020Led | $5 MGrant | |
Agilvax | May 2019Led | $2 MGrant | |
Cyteir Therapeutics | Jun 2016Led | $2 MGrant | |
Levee Medical | Sep 2026Led | $2 MGrant | |
Tempo Therapeutics | Sep 2026Led | $1 MGrant | |
Illuminant Surgical | Apr 2026Participated | $8 MSeed | |
Vivere Oncotherapies | Jan 2026Participated | $10 MOther Equity | |
mPath Health | Mar 2024Participated | $1 MOther Equity | |
Modifi Bio | Oct 2022Led | $2 MGrant | |
miRecule | May 2021Participated | $6 MSeed | |
Outcomes4Me | Nov 2020Participated | $5 MOther Equity | |
Agilvax | Aug 2020Led | $1 MGrant | |
Tvardi Therapeutics | Jul 2020Led | $5 MGrant | |
Agilvax | May 2019Led | $2 MGrant | |
Cyteir Therapeutics | Jun 2016Led | $2 MGrant |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 2 |
| Other Equity | 0 | 3 |
| Grant | 13 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '09 | 1 |
| Oct '09 | 0 |
| Nov '09 | 0 |
| Dec '09 | 0 |
| Jan '10 | 0 |
| Feb '10 | 0 |
| Mar '10 | 0 |
| Apr '10 | 0 |
| May '10 | 0 |
| Jun '10 | 0 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 0 |
| Oct '10 | 0 |
| Nov '10 | 0 |
| Dec '10 | 0 |
| Jan '11 | 0 |
| Feb '11 | 0 |
| Mar '11 | 0 |
| Apr '11 | 0 |
| May '11 | 0 |
| Jun '11 | 0 |
| Jul '11 | 0 |
| Aug '11 | 0 |
| Sep '11 | 0 |
| Oct '11 | 0 |
| Nov '11 | 1 |
| Dec '11 | 0 |
| Jan '12 | 0 |
| Feb '12 | 0 |
| Mar '12 | 0 |
| Apr '12 | 0 |
| May '12 | 0 |
| Jun '12 | 0 |
| Jul '12 | 0 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 0 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 0 |
| Feb '13 | 0 |
| Mar '13 | 0 |
| Apr '13 | 0 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 0 |
| Nov '13 | 0 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 0 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 1 |
| Oct '14 | 1 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 0 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 2 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 1 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 1 |
| Aug '20 | 1 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 1 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 1 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 1 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 2 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 18 |
| Networks, Cloud & Communication | 1 |
| Manufacturing | 1 |
| AI & Machine Learning | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 14 |
| $5M-$10M | 3 |
| $10M-$25M | 1 |
| $25M-$50M | 0 |
| $50M-$100M | 0 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 17 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Alexandria Venture Investments | 1 |
| Alumni Ventures | 1 |
| Asset Management Ventures | 1 |
| Atlanta Technology Angels | 1 |
| Berkeley Frontier Fund | 1 |
| Boutique Venture Partners | 1 |
| DRF | 1 |
| Elderberry Ventures | 1 |
| FCP Ventures | 1 |
| First Launch Capital | 1 |
| Freeflow Ventures | 1 |
| FSHD Society | 1 |
| Maryland Momentum Fund | 1 |
| Merstal | 1 |
| National Institute on Aging | 1 |
| National Science Foundation | 1 |
| Pathway BioVentures | 1 |
| Pillar VC | 1 |
| RTP Angel Fund | 1 |
| Sierra Ventures | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 13 | 72% |
| Participating | 5 | 28% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 13 | 100% |
| Co-led | 0 | 0% |
Team
Senior Investigator
Leader, Pediatric Cancer Immunotherapy Trials Network
Program Director at Coordinating Center for Clinical Trials
Scientific and Commercialization Advisor
NIH Life Sciences Summit Mentor
Senior Invention Development Specialist
Director, The Cancer Genome Atlas Program Office
The Social Media Coordinator